SUMMARY The antiviral acycloguanasine has been compared with adenine arabinoside in the topical treatment of herpes simplex comeal ulcers. It has been found to be at least as good in terms of rate of healing and resolution of symptoms, with ulcers healing in an average of 4-2 days on the acyclovir treatment compared with 6-3 days after adenine arabinoside.
Recent work has shown that the new antiviral acyclovir (acycloguanasine) is a highly effective antiviral drug against the herpes simplex virus."2 It acts mainly on virally infected cells by blocking viral particle formation before the particles pass through the nuclear membrane3 by means of inhibiting viral DNA polymerase after being converted by virally specific thymidine kinase.4 In tissue culture it has been shown to have an antiviral potency greater than the currently available antivirals.5 It has been successfully used in the treatment of experimental herpes simplex infection,' being at least as effective as idoxuridine and triflurothymidine. ' Clinically in the topical treatment of dendritic ulcers after minimal debridement it prevents early recurrence," is at least as effective as idoxuridine,'213 and has been successfully used in ulcers due to either idoxuridine or adenine arabinoside clinical resistance. ' If the patients were on steroids at entry into the trial, they were weaned off them, with the steroid concentration decreased by log dilutions at 2-weekly intervals.
If the ulcer reappeared at the same site within 14 days of stopping the treatment, the patient was treated with the same coded antiviral agent, and the ulcer was designated a recrudescent ulcer. If an ulcer appeared after 14 days at the same site, it was given the same coded treatment and designated a recurrent ulcer. A new ulcer occurring at a new site was also given the same coded antiviral treatment.
Investigations. At each visit the symptoms of pain, pricking, photophobia, and lacrimation were scored from 0 to 3+. The shape of the ulcer was measured and recorded together with the degree of fluorescein and rose Bengal staining, and any stromal involvement or associated uveitis were recorded. The lids, conjunctiva, and cornea were examined for any possible adverse drug reaction.
At the initial visit swabs were taken for culture of the herpes simplex virus, and inoculated into MRC 5 cell line, and kept at 38°C in tubes on a roller drum.
Results
Of the original 60 patients entering the trial 3 were withdrawn on clinical grounds. Twenty-eight patients received acyclovir and 29 ara-A. The groups were evenly matched in most respects (Tables 1 and 2), their symptoms being present for a similar length of time. Treatment was stratified in terms of symptoms being present for more or less than 2 weeks, and there was an even distribution of patients in these categories between the 2 treatment groups. As ulcers that had been present for 10-14 days might have been healing spontaneously, there could be a bias towards one treatment group if all the ulcers in that group had been present for 14 days and in the other group for only a few days, when the ulcer would still be expected to be enlarging due to viral replication. Therefore each treatment group was broken down into subgroups of days from onset of symptoms. There was no difference between the distribution of the 2 treatments (Table 3) . The presence of atopy had no effect on the outcome of treatment, nor did the age of the patient. However, there was a significant difference between the groups in terms of the history of recurrent attacks of cutaneous herpes (p>0-05, x2 test) (Table 1 ). There were more than twice as many small ulcers in the ara-A group as in the acyclovir group, and a larger proportion of large or multiple small dendritic ulcers in the acyclovir groups.
All patients receiving acyclovir healed in an average of 4 5 days. One patient receiving ara-A failed to respond. The remainder receiving ara-A healed in an average of 6-2 days (Table 4) . But a log rank analysis failed to demonstrate a statistically significant differ- Table 4 Outcomeand averagenumberofdays taken to heal in the 2 groups: treatment with either ara-A or Acyclovir The difference between the rates of healing of the 2 groups is not statistically significant (p>005).
group.bmj.com on July 7, 2017 -Published by http://bjo.bmj.com/ Downloaded from ence between the 2 groups in terms of healing ratio at the 5% level (p>005) (Table 4 ) , There was a significant difference though between the groups in terms of the outcome of symptoms, which were scored from 0 to 3+. The average scores at presentation were higher for pain, photophobia. and grittiness in the acyclovir group and lacrimation in the ara-A group. All symptoms apart from grittiness resolved in a shorter time with acyclovir, but only pain resolved in a statistically shorter time in the acyclovir group (Table 2) .
Prior steroid treatment had no effect on the outcome of treatment. In the acyclovir group there were 4 such patients, 2 with recrudescent ulcers occurring 8 and 14 days after initial healing; both subsequently healed with further topical acyclovir.
Fifteen patients in the acyclovir group had an associated stromal infiltration, but none required steroids to suppress this, whereas of 20 patients in the ara-A group 4 required steroids. The stromal infiltration, scored from 0 to 3+, had the same average intensity in each group (15 acyclovir group, 1-6 adenine arabinoside group).
An almost similar number in both groups developed another ulcer or a stromal reaction (disciform keratitis) at a later date, with a maximum of 21 months' follow-up (Table 5) . Two of these ulcers in the adenine arabinoside group developed clinical resistance to the drug but successfully healed when treated with an alternative antiviral. Although the pain score in the acyclovir group was significantly higher, this symptom, together with photophobia and lacrimation, resolved more quickly with acyclovir than with ara-A. It is known that acyclovir penetrates the cornea into the aqueous in theraputic levels, and it is of significance that none of the acyclovir-healed patients required the addition of steroids during treatment to suppress any stromal infiltration compared with 4 of the ara-A group who developed stromal complications requiring steroids. In a further series of patients topical acyclovir alone has been successfully used in suppressing the stromal reaction where there was no overlying dendritic ulceration.
On follow-up there was an equal number in each group developing subsequent disciform or stromal keratitis, and recurrent ulcers. Thus acyclovir does not appear to have any effect in preventing such recurrences. It thus resembles other antivirals, which lead to neither clinical cure nor permanent viral suppression in either animal22 or man.23
Both treatments were well tolerated, and side effects were few. Punctate keratopathy of the conjunctiva in the medial palpebral fissure or the lower fornix was the only side effect seen with either treatment, and there was a higher incidence with ara-A than acyclovir.
Acyclovir appears to have a wide spectrum of activity against the herpes simplex and herpes zoster viruses in preliminary clinical studies. It also has been found to be effective as a topical treatment of herpes zoster keratouveitis (McGill et al. in press). However, clinical resistance to the drug may well develop, as it acts through the DNA polymerase pathway, for which viral lines with a thymidine kinase deficient system have been found. Indeed in cell culture such isolates are already available,2425 so that in future the continued use of the drug may possibly lead to resistant strains being found. 
